Guide · Public records checked September 27, 2026
A sema microdose monthly price: charge, commitment and supply
Read the payment amount, billing period and medicine promise as separate details before treating a monthly headline as a complete quote.
Editorial document research. No clinician review or firsthand treatment experience claimed.
The word monthly looks straightforward until different pages use it for different things. One figure can be a starting price, another a monthly equivalent for a prepaid plan, and another the amount charged at renewal. None of those labels automatically describes the medicine shipment. A useful price comparison begins by keeping these questions apart.
We checked the public CoreAge records on September 27, 2026, without entering a payment flow or obtaining a prescription. Plain Dose Language is part of its promotional publishing network and gives CoreAge disclosed first commercial placement. That relationship is relevant when reading our examples; it does not make an incomplete quote complete or establish a clinical reason to choose treatment.
Read the medicine name before comparing the number
CoreAge's semaglutide microdosing product page advertises a starting figure of $149 per month. The shared microdose landing page includes a semaglutide card at $79 per month and a separate tirzepatide card at $129. Tirzepatide is not an alternative name for semaglutide, so the $129 card should not be counted as a third semaglutide quote.
The $149 and $79 semaglutide figures remain different public records. We do not silently select the cheaper one as a universal offer or describe the difference as a verified billing error. The CoreAge review records their surrounding claims and the limits of what a public page establishes.
Monthly equivalent does not mean monthly payment
The landing page's footer qualifies displayed starting prices as based on a twelve-month plan paid in full. That is materially different from confirming that the displayed monthly figure will be the only amount charged today. A monthly equivalent can help describe a term, but it does not replace the actual payment amount and date.
The same footer says the order's specific price, billing frequency, plan term, renewal date, cancellation method and any early-termination charge are disclosed at checkout. We did not verify those individual terms. An annual qualification should stay beside the advertised number, rather than disappear when the number is repeated in a review or comparison.
A covered service period is not a shipment schedule
A plan can describe a period of clinical access while its medicine record describes something else: the dispensed product and the authorized supply. The word month does not establish whether those periods begin together or whether each charge corresponds to a new shipment. These are questions for the actual agreement, not facts to invent from a headline.
The offer-record comparison separates provider documentation into those categories. For the medicine language, see dose, concentration and volume. A bottle's contents, a quoted service period and a prescribed medicine amount are not interchangeable units for a consumer calculation. No personal usage estimate is needed to notice that the records are incomplete.
No membership fee leaves other questions open
CoreAge uses no-membership-fee and included-service language on its public pages. Those phrases describe aspects of the offer; they do not, by themselves, establish that no recurring authorization, prepaid commitment or separate condition exists. Similarly, a broad shipping claim does not verify the destination, timing or terms of an individual order.
A readable quote should identify what is included in the stated charge and what could create another charge. Clinical evaluation, medication, delivery, follow-up and optional services should be distinguishable even when bundled. Asking for that explanation is different from alleging hidden fees. We have not tested fulfillment or inspected a patient's invoice, and the advertising alone cannot substitute for either.
Cancellation and refund answer different questions
Cancellation concerns ending or changing a future commercial arrangement. A refund concerns money already paid. A short cancel-anytime phrase does not establish that every earlier payment is refundable, that a prepaid term is prorated or that a dispensed medicine can be returned. The exact agreement needs to answer those separate questions.
The FTC's consumer subscription guidance recommends understanding recurring charges and cancellation terms and retaining records. We use that general reading advice, not a claim about a particular legal dispute or current rule's application. CoreAge's public footer also discusses a refund when a clinician finds treatment inappropriate; this is not a verified refund policy for every other circumstance.
Payment certainty is separate from clinical certainty
A detailed price does not establish that a medicine is appropriate or that it will produce a promised result. CoreAge advertises a compounded preparation. FDA explains that compounded drugs do not receive FDA premarket approval for safety, effectiveness and quality. A bundled service price cannot change that regulatory distinction.
The lower-amount safety guide examines the clinical claims separately. Likewise, our AgelessRx review and Noom review consider their own plan documents rather than assuming that every company uses month, included or introductory in the same way. Price clarity and evidence quality are two useful questions, not substitutes for each other.
Preserve the quote instead of reconstructing it later
An order record is easier to understand when it preserves the named medicine or program, total payment, covered period, renewal authorization and relevant cancellation terms together. Keeping the dated page or written clarification can help distinguish the offer a reader saw from a later revision. That record does not need to contain a homemade medicine calculation.
If an advertised number and the presented agreement differ, the useful next step is clarification of that difference before treating either as the settled quote. This guide cannot predict the eventual payment or authorize a treatment change to reduce spending. A clear commercial record supports informed questions; the clinical team still owns decisions about the actual prescribed medicine.
Sources for this article
- CoreAge Rx: Semaglutide Microdosing Therapy ↗Provider product description · Checked 2026-09-27
- CoreAge Rx: shared microdose offer, product cards and footer terms ↗Provider offer and billing descriptions · Checked 2026-09-27
- FTC: Getting In and Out of Free Trials, Auto-Renewals and Negative Option Subscriptions ↗Government consumer information · Checked 2026-09-27
- FDA: Understanding the Risks of Compounded Drugs ↗Regulatory explanation · Checked 2026-09-27